Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3334089 | Seminars in Hematology | 2006 | 6 Pages |
Abstract
Several clinical models have generated insight into the relationship between erythropoietin (EPO), iron, and erythropoiesis. Patients with chronic hemolytic anemias or hemochromatosis can increase erythropoiesis six- to eightfold over basal rates, whereas patients with blood loss, such as those donating autologous blood, can increase erythropoiesis only two- to fourfold over basal levels, even with pharmacologic doses of recombinant human EPO. A substantial limitation to the dose/response relationship between EPO therapy and the erythropoietic response is iron-restricted erythropoiesis, even in the presence of storage iron. Novel approaches to iron supplementation therapy when erythropoietic agents are used are indicated.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Lawrence Tim Goodnough,